Skip to main content

Effect of Lactobacillus acidophilus KFRI342 on the development of chemically induced precancerous growths in the rat colon.

  • 2012-03-01
  • Journal of Medical Microbiology 61(3)
    • Jin-Hee Chang
    • Y. Shim
    • S. Cha
    • M. Reaney
    • K. Chee

Abstract

Lactobacillus acidophilus KFRI342, isolated from the Korean traditional food kimchi, was investigated for its suitability as a dietary probiotic. The effects of L. acidophilus KFRI342 on the development of chemically induced (1,2-dimethylhydrazine; DMH) precancerous cytological changes of the colon were investigated in rats. Forty-five male F344 rats were randomly divided into three dietary groups. The control group received a high-fat diet (HF), a second group received a high-fat diet containing the carcinogen (HFC), and a final group received a high-fat diet containing the carcinogen and L. acidophilus KFRI342 (HFCL). L. acidophilus KFRI342 was administered orally three times per week at 2×10(9) c.f.u. ml(-1). L. acidophilus KFRI342 treatments decreased the number of Escherichia coli in faecal samples, the enzyme activities of β-glucuronidase and β-glucosidase, and plasma triglyceride concentration compared to the HF and HFC treatments (P<0.05). L. acidophilus KFRI342 consumption also decreased the ratio of aberrant crypts to aberrant crypt foci incidence and the number of aberrant crypts in HFCL rats. Therefore, L. acidophilus showed potential probiotic activity as an inhibitor of DMH-induced symptoms in live rats. Our in vivo studies indicate that L. acidophilus from kimchi may be suitable as a probiotic for human use.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus acidophilusReduced Aberrant CryptsBeneficial
Large
Lactobacillus acidophilusReduced Beta-Glucuronidase ActivityBeneficial
Moderate
Lactobacillus acidophilusReduced Fecal E. coli PopulationsBeneficial
Moderate
Lactobacillus acidophilusReduced Plasma TriglyceridesBeneficial
Moderate
Lactobacillus acidophilusReduced β-Glucosidase Enzyme ActivityBeneficial
Moderate
Lactobacillus acidophilus HA-122Reduced Aberrant CryptsBeneficial
Large
Lactobacillus acidophilus HA-122Reduced Fecal Escherichia coli CountBeneficial
Moderate
Lactobacillus acidophilus HA-122Reduced Incidence of Aberrant Crypts Relative to Aberrant Crypt FociBeneficial
Moderate
Lactobacillus acidophilus HA-122Reduced Plasma TriglyceridesBeneficial
Moderate
Lactobacillus acidophilus MAK32L61AReduced Aberrant Crypt FociBeneficial
Large
Lactobacillus acidophilus MAK32L61AReduced Aberrant Crypt Foci IncidenceBeneficial
Large
Lactobacillus acidophilus MAK32L61AReduced E. coli LevelsBeneficial
Moderate
Lactobacillus acidophilus MAK32L61AReduced Plasma TriglyceridesBeneficial
Moderate
Lactobacillus acidophilus R0418Reduced Fecal Escherichia coli CountBeneficial
Moderate
Lactobacillus acidophilus R0418Reduced Incidence of Aberrant CryptsBeneficial
Large
Lactobacillus acidophilus R0418Reduced Plasma TriglyceridesBeneficial
Moderate
Lactobacillus acidophilus SD-5212Reduced Aberrant CryptsBeneficial
Large
Lactobacillus acidophilus SD-5212Reduced E. coli LevelsBeneficial
Moderate
Lactobacillus acidophilus SD-5212Reduced Incidence of Aberrant Crypts Relative to Aberrant Crypt FociBeneficial
Moderate
Lactobacillus acidophilus SD-5212Reduced Plasma TriglyceridesBeneficial
Moderate
Lactobacillus acidophilus UALa01Reduced Aberrant Crypt IncidenceBeneficial
Moderate
Lactobacillus acidophilus UALa01Reduced Aberrant Crypt NumberBeneficial
Moderate
Lactobacillus acidophilus UALa01Reduced Escherichia Coli LevelsBeneficial
Moderate
Lactobacillus acidophilus UALa01Reduced Plasma TriglyceridesBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.